metformin has been researched along with Cyst in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways." | 9.27 | A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018) |
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 7.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys." | 5.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| "Racemose neurocysticercosis is an aggressive infection caused by the aberrant expansion of the cyst form of Taenia solium within the subarachnoid spaces of the human brain and spinal cord, resulting in the displacement of the surrounding host tissue and chronic inflammation." | 5.72 | Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment. ( Garcia, HH; Nash, TE; Orrego, MA; Vasquez, CM; Verastegui, MR, 2022) |
| "Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways." | 5.27 | A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018) |
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 3.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "Since ADPKD is a complex disease with a high degree of interindividual heterogeneity, and the mechanisms involved in cyst growth also have important functions in various physiological processes, it may prove difficult to develop drugs that target cyst growth without causing major adverse events." | 2.82 | Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. ( Bais, T; Gansevoort, RT; Meijer, E, 2022) |
| "Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys." | 1.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| "Racemose neurocysticercosis is an aggressive infection caused by the aberrant expansion of the cyst form of Taenia solium within the subarachnoid spaces of the human brain and spinal cord, resulting in the displacement of the surrounding host tissue and chronic inflammation." | 1.72 | Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment. ( Garcia, HH; Nash, TE; Orrego, MA; Vasquez, CM; Verastegui, MR, 2022) |
| "Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves over-proliferation of cyst-lining epithelial cells and excessive cystic fluid secretion." | 1.72 | PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity. ( Fang, Q; Fu, K; Guo, D; Liu, H; Ren, Y; Su, L; Wang, J; Wang, R; Yin, L; Yuan, H; Zhang, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MY | 2 |
| Tsai, CY | 1 |
| Chou, LF | 1 |
| Hsu, SH | 1 |
| Yang, HY | 1 |
| Hung, CC | 2 |
| Tian, YC | 2 |
| Ong, ACM | 1 |
| Yang, CW | 2 |
| Orrego, MA | 1 |
| Verastegui, MR | 1 |
| Vasquez, CM | 1 |
| Garcia, HH | 1 |
| Nash, TE | 1 |
| Su, L | 1 |
| Yuan, H | 1 |
| Zhang, H | 1 |
| Wang, R | 1 |
| Fu, K | 1 |
| Yin, L | 1 |
| Ren, Y | 1 |
| Liu, H | 1 |
| Fang, Q | 1 |
| Wang, J | 1 |
| Guo, D | 1 |
| Bais, T | 1 |
| Gansevoort, RT | 1 |
| Meijer, E | 1 |
| Oto, OA | 1 |
| Atwood, DJ | 1 |
| Chaudhary, A | 1 |
| He, Z | 1 |
| Li, AS | 1 |
| Wempe, MF | 1 |
| Edelstein, CL | 1 |
| Leonhard, WN | 1 |
| Song, X | 1 |
| Kanhai, AA | 1 |
| Iliuta, IA | 1 |
| Bozovic, A | 1 |
| Steinberg, GR | 1 |
| Peters, DJM | 1 |
| Pei, Y | 1 |
| Sato, Y | 2 |
| Qiu, J | 1 |
| Hirose, T | 1 |
| Miura, T | 1 |
| Kohzuki, M | 1 |
| Ito, O | 1 |
| Ma, TL | 1 |
| Chen, YC | 1 |
| Cheng, YC | 1 |
| Seliger, SL | 1 |
| Abebe, KZ | 1 |
| Hallows, KR | 1 |
| Miskulin, DC | 1 |
| Perrone, RD | 1 |
| Watnick, T | 1 |
| Bae, KT | 1 |
1 review available for metformin and Cyst
| Article | Year |
|---|---|
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.
Topics: Cysts; Disease Progression; Humans; Metformin; Polycystic Kidney, Autosomal Dominant; Somatostatin | 2022 |
2 trials available for metformin and Cyst
| Article | Year |
|---|---|
Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
Topics: Animals; Cysts; Disease Models, Animal; Female; Kidney; Lactic Acid; Male; Metformin; Mice; Mice, Tr | 2022 |
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Topics: Adolescent; Adult; Clinical Trials, Phase II as Topic; Cysts; Disease Progression; Dose-Response Rel | 2018 |
6 other studies available for metformin and Cyst
| Article | Year |
|---|---|
Proliferative cells in racemose neurocysticercosis have an active MAPK signalling pathway and respond to metformin treatment.
Topics: Animals; Cysts; Humans; Metformin; Mice; Mitogen-Activated Protein Kinases; Neurocysticercosis; Taen | 2022 |
PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Cystic Fibrosis Transmembrane Condu | 2022 |
Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Cysts; Humans; Lactates; Male; Metformin; Polycystic Kidney | 2023 |
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cyclic AMP; | 2019 |
Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
Topics: AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cysts; Disease Progression; Enzyme Activ | 2021 |
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cell Proliferation; Cloaca; Cysts; Disease Models | 2017 |